Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ben Carson joins Galectin Therapeutics as ‘special consultant’ 

By Brian Buntz | April 21, 2021

Galectin TherapeuticsFormer HUD Secretary Dr. Ben Carson, Sr. will assist Galectin Therapeutics Inc. (NSDQ: GALT) with the development of its galectin-3 inhibitor, belapectin. The drug is a potential treatment for nonalcoholic steatohepatitis (NASH), which is also known as nonalcoholic fatty liver disease. 

Galectin Therapeutics has an ongoing Phase 2b/3 trial to investigate belapectin’s potential in treating cirrhosis associated with NASH and other fibrotic diseases. 

Galectin Therapeutics will make Carson responsible for forming a scientific advisory committee for the company. 

In related news, Biopharma Ovid Therapeutics (NSDQ:OVID) has recently announced it had hired a well-known leader — MIT professor Robert Langer — to lead an advisory group. That company installed famed inventor Robert Langer as the leader of its scientific advisory committee. 

At Galectin Therapeutics, Carson will advise in recruiting commercial and academic partners. 

“We are proud to announce our engagement with Dr. Carson, whose scientific and medical knowledge will be invaluable to the Company as we move forward with our current trials in NASH cirrhosis and cancer immunotherapy,” said Joel Lewis, Galectin Therapeutics CEO, in a statement. 

Referring to his appointment, Carson stated, “Galectin Therapeutics and its drug candidate, belapectin, are at the forefront of research into galectin inhibition, which appears to be implicated in many diseases, including NASH cirrhosis, which is a large unmet medical need.” 

Carson said that early data suggest that belapectin could be used in tandem with immunotherapy to treat cancer and other disorders that involve galectin-3. 


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: belapectin, Ben Carson, Galectin Therapeutics, NASH, Nonalcoholic steatohepatitis
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 
FDA logo
FDA could approve MDMA and psilocybin in 2 years

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50